Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03631706
Title M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

lung non-small cell carcinoma

Therapies

M7824

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST